Literature DB >> 32103145

Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.

Diane Libert1, Constance M Yuan2, Katherine E Masih3, Pallavi Galera2, Dalia Salem2, Haneen Shalabi1, Bonnie Yates1, Cindy Delbrook1, Jack F Shern1, Terry J Fry1,4, Javed Khan3, Maryalice Stetler-Stevenson2, Nirali N Shah5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32103145      PMCID： PMC8919057          DOI： 10.1038/s41375-020-0760-x

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  CAR T cells better than BiTEs.

Authors:  John C Molina; Nirali N Shah
Journal:  Blood Adv       Date:  2021-01-26

Review 2.  Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.

Authors:  Leila Amini; Sara K Silbert; Nirali N Shah; Mohamed Abou-El-Enein; Shannon L Maude; Loretta J Nastoupil; Carlos A Ramos; Renier J Brentjens; Craig S Sauter
Journal:  Nat Rev Clin Oncol       Date:  2022-03-22       Impact factor: 66.675

3.  Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.

Authors:  Regina M Myers; Agne Taraseviciute; Seth M Steinberg; Adam J Lamble; Jennifer Sheppard; Bonnie Yates; Alexandra E Kovach; Brent Wood; Michael J Borowitz; Maryalice Stetler-Stevenson; Constance M Yuan; Vinodh Pillai; Toni Foley; Perry Chung; Lee Chen; Daniel W Lee; Colleen Annesley; Amanda DiNofia; Stephan A Grupp; Samuel John; Deepa Bhojwani; Patrick A Brown; Theodore W Laetsch; Lia Gore; Rebecca A Gardner; Susan R Rheingold; Michael A Pulsipher; Nirali N Shah
Journal:  J Clin Oncol       Date:  2021-11-12       Impact factor: 44.544

4.  Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy.

Authors:  Nam Gyu Im; Amy Guillaumet-Adkins; Jens G Lohr; Birgit Knoechel; Megha Wal; Anna J Rogers; Julia Frede; Claire C Havig; Jing Yang; Praveen Anand; Sarah K Stegmann; Johannes M Waldschmidt; Noori Sotudeh; Leili Niu; Jordan Voisine; Michal R Schweiger; Clemens Grassberger
Journal:  Cancer Immunol Res       Date:  2022-09-01       Impact factor: 12.020

5.  HLA-independent T cell receptors for targeting tumors with low antigen density.

Authors:  Jorge Mansilla-Soto; Justin Eyquem; Sascha Haubner; Mohamad Hamieh; Judith Feucht; Noémie Paillon; Andrés Ernesto Zucchetti; Zhuoning Li; Maria Sjöstrand; Pieter L Lindenbergh; Michelle Saetersmoen; Anton Dobrin; Mathieu Maurin; Archana Iyer; Andreina Garcia Angus; Matthew M Miele; Zeguo Zhao; Theodoros Giavridis; Sjoukje J C van der Stegen; Fella Tamzalit; Isabelle Rivière; Morgan Huse; Ronald C Hendrickson; Claire Hivroz; Michel Sadelain
Journal:  Nat Med       Date:  2022-01-13       Impact factor: 87.241

6.  Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.

Authors:  Martijn W C Verbeek; Chiara Buracchi; Anna Laqua; Stefan Nierkens; Lukasz Sedek; Juan Flores-Montero; Mattias Hofmans; Elaine Sobral de Costa; Michaela Nováková; Ester Mejstrikova; Susana Barrena; Saskia Kohlscheen; Monika Szczepanowski; Jan Kulis; Elen Oliveira; Romana Jugooa; Anja X de Jong; Tomasz Szczepanski; Jan Philippé; Jacques J M van Dongen; Alberto Orfao; Monika Brüggemann; Giuseppe Gaipa; Vincent H J van der Velden
Journal:  Br J Haematol       Date:  2021-12-08       Impact factor: 8.615

7.  Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.

Authors:  Ekaterina Mikhailova; Olga Illarionova; Larisa Shelikhova; Elena Zerkalenkova; Olga Molostova; Yulia Olshanskaya; Galina Novichkova; Alexey Maschan; Michael Maschan; Alexander Popov
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

8.  Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy.

Authors:  Alexandra Semchenkova; Ekaterina Mikhailova; Alexander Komkov; Marina Gaskova; Ruslan Abasov; Evgenii Matveev; Marat Kazanov; Ilgar Mamedov; Anna Shmitko; Vera Belova; Anna Miroshnichenkova; Olga Illarionova; Yulia Olshanskaya; Grigory Tsaur; Tatiana Verzhbitskaya; Natalia Ponomareva; Gleb Bronin; Konstantin Kondratchik; Larisa Fechina; Yulia Diakonova; Liudmila Vavilova; Natalia Myakova; Galina Novichkova; Alexey Maschan; Michael Maschan; Elena Zerkalenkova; Alexander Popov
Journal:  Int J Mol Sci       Date:  2022-04-05       Impact factor: 5.923

Review 9.  Antigen Loss after Targeted Immunotherapy in Hematological Malignancies.

Authors:  Ting Zhou; Hao-Wei Wang
Journal:  Clin Lab Med       Date:  2021-07-02       Impact factor: 2.172

10.  Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Authors:  George Mo; Hao-Wei Wang; Aimee C Talleur; Shilpa A Shahani; Bonnie Yates; Haneen Shalabi; Michael G Douvas; Katherine R Calvo; Jack F Shern; Sridhar Chaganti; Katharine Patrick; Young Song; Terry J Fry; Xiaolin Wu; Brandon M Triplett; Javed Khan; Rebecca A Gardner; Nirali N Shah
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.